舒眠胶囊联合盐酸帕罗西汀片治疗抑郁症伴失眠临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R277.7;R256.23

基金项目:


Clinical Study on Shumian Capsules Combined with Paroxetine Hydrochloride Tablets for Depression Complicated with Insomnia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察舒眠胶囊联合盐酸帕罗西汀片治疗抑郁症伴失眠的临床疗效。方法:选取108 例抑郁症伴失眠患者,按照随机数字表法分为观察组和对照组,每组54 例。观察组予以舒眠胶囊联合盐酸帕罗西汀片治疗,对照组仅予以盐酸帕罗西汀片治疗,2 组均治疗4 周。采用匹兹堡睡眠质量指数(PSQI)、汉密尔顿焦虑量表(HAMA)-14、汉密尔顿抑郁量表(HAMD)-24、世界卫生组织生存质量测定量表(WHOQOL-BREF)评价2 组治疗前后的睡眠质量、焦虑程度、抑郁程度及生活质量,比较2 组临床疗效及不良反应发生率。结果:治疗1 周、2 周、4 周,2 组PSQI 评分均较治疗前降低(P<0.05),观察组PSQI 评分均低于同期对照组(P<0.05)。治疗后,2 组HAMA-14 及HAMD-24 评分均较治疗前降低(P<0.05),观察组HAMA-14 及HAMD-24 评分均低于对照组(P<0.05)。治疗后,2 组生理领域、心理领域、社会关系、环境领域及总体评价评分均较治疗前升高(P<0.05),观察组WHOQOL-BREF 上述各维度评分均高于对照组(P<0.05)。观察组总有效率88.89%,高于对照组74.07% (P<0.05)。观察组不良反应发生率16.67%,与对照组11.11%比较,差异无统计学意义(P>0.05)。结论:舒眠胶囊联合盐酸帕罗西汀片治疗抑郁症伴失眠,可有效改善患者的睡眠质量、生活质量和焦虑、抑郁情绪,且安全性好。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Shumian capsules combined with paroxetine hydrochloride tablets for depression complicated with insomnia. Methods:A total of 108 cases of patients with depression complicated with insomnia were selected and divided into the observation group and the control group according to the random number table method,with 54 cases in each group. The observation group was treated with Shumian capsules combined with paroxetine hydrochloride tablets,and the control group was simply treated with paroxetine hydrochloride tablets. Both groups were treated for four weeks. Before and after treatment,the sleep quality,anxiety degree,depressive degree and quality of life in the two groups were evaluated by Pittsburgh Sleep Quality Index(PSQI),Hamilton Anxiety Scale(HAMA) - 14, Hamilton Depression Scale(HAMD) - 24 and World Health Organization Quality of Life- BREF(WHOQOLBREF). The clinical effects and the incidence of adverse reactions in the two groups were compared. Results:After one,two and four weeks of treatment,the PSQI scores in the two groups were decreased when compared with those before treatment(P<0.05),the PSQI score in the observation group was lower than that in the control group at the same period(P<0.05). After treatment,the scores of HAMA- 14 and HAMD-24 in the two groups were decreased when compared with those before treatment(P<0.05),and the scores of HAMA-14 and HAMD-24 in the observation group were lower than those in the control group (P<0.05). After treatment,the scores of physiology,psychology,social relations,environment and total evaluation in the two groups were increased when compared with those before treatment(P<0.05), and the above scores of all dimensions in WHOQOL-BREF in the observation group were higher than those in the control group(P<0.05). The total effective rate was 88.89% in the observation group,higher than that of 74.07% in the control group(P<0.05). The incidence of adverse reactions was 16.67% in the observation group and 11.11% in the control group,there being no significance in the difference(P>0.05). Conclusion: Shumian capsules combined with paroxetine hydrochloride tablets for depression complicated with insomnia can effectively improve sleep quality,quality of life,anxiety and depression,with good safety.

    参考文献
    相似文献
    引证文献
引用本文

杜承容,颜福阳,张仙红.舒眠胶囊联合盐酸帕罗西汀片治疗抑郁症伴失眠临床研究[J].新中医,2022,54(20):44-47

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-10-28
  • 出版日期:
文章二维码